<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134393</url>
  </required_header>
  <id_info>
    <org_study_id>1235.33</org_study_id>
    <secondary_id>2009-017336-40</secondary_id>
    <nct_id>NCT01134393</nct_id>
  </id_info>
  <brief_title>TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch</brief_title>
  <official_title>A Prospective, Open-label TElmisartan/AMlodipine Single Pill STudy to Assess the Efficacy in Patients With Essential Hypertension&quot;...&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The general aim of this trial to determine the efficacy as measured by the percentage of
      patients reaching blood pressure goal at the end of the treatment period at 12 weeks.
      In-clinic blood pressures, home blood pressures and safety will be carefully monitored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Achieving BP control is defined as SBP&lt;140 mmHg and DBP&lt;90 mmHg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BP Control After 4 and 8 Weeks of Treatment Using In-clinic BP Measurements.</measure>
    <time_frame>4 and 8 weeks</time_frame>
    <description>Achieving BP control is defined as SBP&lt;140 mmHg and DBP&lt;90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Control (Morning and Evening) After 12 Weeks of Treatment Using Home Blood Pressure Measurement (HBPM).</measure>
    <time_frame>Week 12</time_frame>
    <description>Achieving BP control with HBPM is defined as SBP&lt;135 mmHg and DBP&lt;85 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in In-clinic Measured Mean SBP and Mean DBP</measure>
    <time_frame>weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in In-clinic Measured Mean Pulse Rate</measure>
    <time_frame>weeks 4, 8 and 12</time_frame>
    <description>Pulse pressure was not analysed for this study instead pulse rate was analysed at weeks 4, 8 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in In-clinic Measured Mean Pulse Pressure</measure>
    <time_frame>weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP and SBP Control and Response Rates After 4, 8 and 12 Weeks of Treatment Using In-clinic BP Measurements</measure>
    <time_frame>weeks 4, 8 and 12</time_frame>
    <description>DBP control is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP &lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=10mmHg. SBP response is defined as SBP&lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=15mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Blood Pressure Categories Over Time</measure>
    <time_frame>weeks 4, 8 and 12</time_frame>
    <description>BP optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg, BP normal: SBP &lt;130 mmHg and DBP &lt;85 mmHg but not optimal, BP high-normal: SBP &lt;140 mmHg and DBP &lt;90 mmHg but not normal. Grade 1 hypertension: SBP &lt;160 mmHg and DBP &lt;100 mmHg but not high-normal, Grade 2 hypertension: SBP &lt;180 mmHg and DBP &lt;110 mmHg but not grade 1, Grade 3 hypertension: SBP &gt;=180 mmHg or DBP &gt;=110 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP and SBP Control and Response Rates Morning and Evening Over Time HBPM Measurements</measure>
    <time_frame>weeks 4, 8 and 12</time_frame>
    <description>DBP control: DBP &lt;85 mmHg, SBP control: SBP &lt;135 mmHg, DBP response: DBP &lt;85 mmHg or a reduction from baseline &gt;=10 mmHg, SBP response: SBP &lt;135 mmHg or a reduction from baseline &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Patients Requiring Up-titration to Telmisartan 80mg Plus Amlodipine 10mg Combination (T80/A10) to Achieve Blood Pressure Control Over Time</measure>
    <time_frame>weeks 4 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>telmisartan/amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>start low dose and uptitrate to high dose on the basis of blood pressure goal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan/amlodipine</intervention_name>
    <description>start low dose and uptitrate to high dose on the basis of BP goal</description>
    <arm_group_label>telmisartan/amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Ability to provide written informed consent in accordance with Good Clinical Practice
             and local legislation

          2. Age 18 years or older

          3. Patients with uncontrolled hypertension as defined SBP &gt; 140 mmHg and SBP &gt; 130 mmHg
             in patients with diabetes or renal impairment or DBP &gt; 90 mmHg and DBP &gt;80 mmHg in
             patients with diabetes or renal impairment after at least an 6 weeks of stable
             treatment with antihypertensive medication defined as treatment with the clinically
             recommended dose of a single RAAS blocking agent (Angiotensin Converting Enzym
             inhibition, AII Receptor Blocker and Direct Renin Inhibitor) at entering the trial.
             Renal impairment is defined as a creatinine &gt;133µmol/l (1.5mg/dl) in male patients and
             a creatinine &gt;124µmol/l (1.3mg/dl) in female patients or a creatinine clearance
             between 30-60 ml/min

        Exclusion criteria:

          1. Pre-menopausal women who are not surgically sterile; or are nursing or pregnant; or
             are not practising acceptable means of birth control or do not plan to continue using
             acceptable means of birth control throughout the study and do not agree to submit to
             pregnancy testing during participation in the trial. Acceptable methods of birth
             control include the transdermal patch, oral, implantable or injectable contraceptives,
             sexual abstinence and vasectomised partner.

          2. Known or suspected secondary hypertension (e.g., renal artery stenosis or
             phaeochromocytoma).

          3. Mean in-clinic seated cuff Systolic BP &gt;180 mmHg and SBP &gt;160 mmHg in patients with
             diabetes or renal impairment or Diastolic BP &gt;110 mmHg and DBP &gt;100 mmHg in patients
             with diabetes or renal impairment. Renal impairment is defined as a creatinine
             &gt;133µmol/l (1.5mg/dl) in male patients and a creatinine &gt;124µmol/l (1.3mg/dl) in
             female patients or a creatinine clearance between 30-60 ml/min.

          4. Renal dysfunction as defined by the following laboratory parameters: Serum creatinine
             &gt;3.0 mg/dl (or &gt;265 ¿mol/L) and/or known creatinine clearance of &lt;30 ml/min and/or
             clinical markers of severe renal impairment.

          5. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney,
             post-renal transplant patients or patients with only one kidney.

          6. Clinically relevant hypokalaemia or hyperkalaemia (i.e., &lt;3.5 or &gt;5.5 mEq/L).

          7. Uncorrected sodium or volume depletion.

          8. Primary aldosteronism.

          9. Hereditary fructose intolerance.

         10. Congestive heart failure New York Heart Association functional class Congestive Heart
             Failure III-IV (Refer to Appendix 10.1).

         11. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or
             other clinically relevant cardiac arrhythmias as determined by the Investigator.

         12. Biliary obstructive disorders (e.g., cholestasis) or hepatic insufficiency (defined as
             elevated levels of &gt;2x bilirubin or &gt;2x transaminases values). (Refer to Appendix
             10.3)

         13. Patients who have previously experienced symptoms characteristic of angioedema during
             treatment with ACE inhibitors or angiotensin-II receptor antagonists.

         14. History of drug or alcohol dependency within six months prior to signing the informed
             consent form.

         15. Any investigational drug therapy within one month of signing the informed consent.

         16. Known hypersensitivity to any component of the trial drugs (telmisartan or
             amlodipine).

         17. History of non-compliance or inability to comply with prescribed medications or
             protocol procedures.

         18. Any other clinical condition which, in the opinion of the investigator, would not
             allow safe completion of the protocol and safe administration of the trial medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.33.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haag</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rednitzhembach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rodgau-Dudenhofen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterschneidheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westerkappeln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Aquila</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stradella (PV)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.52004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.52007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.52006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.52009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.52008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>'s Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beek en Donk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beerzerveld</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ermelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lichtenvoorde</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Musselkanaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijverdal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wildervank</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chorzow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dabrowa Gornicza</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Piotrkow Trybunalski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tychy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tychy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.33.48007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <results_first_submitted>May 31, 2012</results_first_submitted>
  <results_first_submitted_qc>May 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2012</results_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a prospective, single-arm, open-label, uncontrolled, multi-centre, international trial. Whilst 542 patients were enrolled, 502 entered the study. Since one patient refused to take study medication, only 501 patients were treated. The Full analysis set (FAS) consisted of 494 patients and this is the basis of most data presentations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>T80/A5</title>
          <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="501">Entered and treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="449">Completed trial medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T80/A5</title>
          <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="494"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>number</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure (SBP) at time of baseline</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure (DBP) at time of baseline</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.8" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.</title>
        <description>Achieving BP control is defined as SBP&lt;140 mmHg and DBP&lt;90 mmHg.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full Analysis Set (FAS) is defined as all patients who took at least one dose of trial medication, and for whom a baseline measurement and at least one post-baseline efficacy measurement were available. Last observation carried forward (LOCF) will be used.</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.</title>
          <description>Achieving BP control is defined as SBP&lt;140 mmHg and DBP&lt;90 mmHg.</description>
          <population>Full Analysis Set (FAS) is defined as all patients who took at least one dose of trial medication, and for whom a baseline measurement and at least one post-baseline efficacy measurement were available. Last observation carried forward (LOCF) will be used.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6" lower_limit="63.3" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control After 4 and 8 Weeks of Treatment Using In-clinic BP Measurements.</title>
        <description>Achieving BP control is defined as SBP&lt;140 mmHg and DBP&lt;90 mmHg.</description>
        <time_frame>4 and 8 weeks</time_frame>
        <population>FAS and LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control After 4 and 8 Weeks of Treatment Using In-clinic BP Measurements.</title>
          <description>Achieving BP control is defined as SBP&lt;140 mmHg and DBP&lt;90 mmHg.</description>
          <population>FAS and LOCF</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Control (Morning and Evening) After 12 Weeks of Treatment Using Home Blood Pressure Measurement (HBPM).</title>
        <description>Achieving BP control with HBPM is defined as SBP&lt;135 mmHg and DBP&lt;85 mmHg.</description>
        <time_frame>Week 12</time_frame>
        <population>FAS and LOCF and with at least one post baseline HBPM measurement</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control (Morning and Evening) After 12 Weeks of Treatment Using Home Blood Pressure Measurement (HBPM).</title>
          <description>Achieving BP control with HBPM is defined as SBP&lt;135 mmHg and DBP&lt;85 mmHg.</description>
          <population>FAS and LOCF and with at least one post baseline HBPM measurement</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Over Time in In-clinic Measured Mean SBP and Mean DBP</title>
        <time_frame>weeks 4, 8 and 12</time_frame>
        <population>FAS with non-missing data</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Over Time in In-clinic Measured Mean SBP and Mean DBP</title>
          <population>FAS with non-missing data</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at week 4 SBP (N=485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.58" spread="11.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 8 SBP (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.37" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 12 SBP (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.92" spread="12.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 4 DBP (N=485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.24" spread="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 8 DBP (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.33" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 12 DBP (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.43" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Over Time in In-clinic Measured Mean Pulse Rate</title>
        <description>Pulse pressure was not analysed for this study instead pulse rate was analysed at weeks 4, 8 and 12.</description>
        <time_frame>weeks 4, 8 and 12</time_frame>
        <population>Treated Set (TS) with non-missing data</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Over Time in In-clinic Measured Mean Pulse Rate</title>
          <description>Pulse pressure was not analysed for this study instead pulse rate was analysed at weeks 4, 8 and 12.</description>
          <population>Treated Set (TS) with non-missing data</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at week 4 (N=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 8 (N=463)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 12 (N=344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Over Time in In-clinic Measured Mean Pulse Pressure</title>
        <time_frame>weeks 4, 8 and 12</time_frame>
        <population>There was no information in the Case Report Form (CRF)</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Over Time in In-clinic Measured Mean Pulse Pressure</title>
          <population>There was no information in the Case Report Form (CRF)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP and SBP Control and Response Rates After 4, 8 and 12 Weeks of Treatment Using In-clinic BP Measurements</title>
        <description>DBP control is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP &lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=10mmHg. SBP response is defined as SBP&lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=15mmHg.</description>
        <time_frame>weeks 4, 8 and 12</time_frame>
        <population>FAS and LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>DBP and SBP Control and Response Rates After 4, 8 and 12 Weeks of Treatment Using In-clinic BP Measurements</title>
          <description>DBP control is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP &lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=10mmHg. SBP response is defined as SBP&lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=15mmHg.</description>
          <population>FAS and LOCF</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 DBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 DBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 DBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 SBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 SBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 SBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 DBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 DBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 DBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 SBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 SBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 SBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Blood Pressure Categories Over Time</title>
        <description>BP optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg, BP normal: SBP &lt;130 mmHg and DBP &lt;85 mmHg but not optimal, BP high-normal: SBP &lt;140 mmHg and DBP &lt;90 mmHg but not normal. Grade 1 hypertension: SBP &lt;160 mmHg and DBP &lt;100 mmHg but not high-normal, Grade 2 hypertension: SBP &lt;180 mmHg and DBP &lt;110 mmHg but not grade 1, Grade 3 hypertension: SBP &gt;=180 mmHg or DBP &gt;=110 mmHg.</description>
        <time_frame>weeks 4, 8 and 12</time_frame>
        <population>FAS with non-missing data</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Blood Pressure Categories Over Time</title>
          <description>BP optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg, BP normal: SBP &lt;130 mmHg and DBP &lt;85 mmHg but not optimal, BP high-normal: SBP &lt;140 mmHg and DBP &lt;90 mmHg but not normal. Grade 1 hypertension: SBP &lt;160 mmHg and DBP &lt;100 mmHg but not high-normal, Grade 2 hypertension: SBP &lt;180 mmHg and DBP &lt;110 mmHg but not grade 1, Grade 3 hypertension: SBP &gt;=180 mmHg or DBP &gt;=110 mmHg.</description>
          <population>FAS with non-missing data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BP optimal at week 4 (N=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP normal at week 4 (N=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP high-normal at week 4 (N=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 hypertension at week 4 (N=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 hypertension at week 4 (N=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hypertension at week 4 (N=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP optimal at week 8 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP normal at week 8 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP high-normal at week 8 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 hypertension at week 8 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 hypertension at week 8 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hypertension at week 8 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP optimal at week 12 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP normal at week 12 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP high-normal at week 12 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 hypertension at week 12 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 hypertension at week 12 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hypertension at week 12 (N=487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP and SBP Control and Response Rates Morning and Evening Over Time HBPM Measurements</title>
        <description>DBP control: DBP &lt;85 mmHg, SBP control: SBP &lt;135 mmHg, DBP response: DBP &lt;85 mmHg or a reduction from baseline &gt;=10 mmHg, SBP response: SBP &lt;135 mmHg or a reduction from baseline &gt;= 15 mmHg</description>
        <time_frame>weeks 4, 8 and 12</time_frame>
        <population>FAS and LOCF and with at least one post baseline HBPM measurement</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>DBP and SBP Control and Response Rates Morning and Evening Over Time HBPM Measurements</title>
          <description>DBP control: DBP &lt;85 mmHg, SBP control: SBP &lt;135 mmHg, DBP response: DBP &lt;85 mmHg or a reduction from baseline &gt;=10 mmHg, SBP response: SBP &lt;135 mmHg or a reduction from baseline &gt;= 15 mmHg</description>
          <population>FAS and LOCF and with at least one post baseline HBPM measurement</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP control morning at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP control morning at week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP control morning at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP control evening at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP control evening at week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP control evening at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP control morning at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP control morning at week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP control morning at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP control evening at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP control evening at week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP control evening at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP response morning at week 4 (N=354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP response morning at week 8 (N=354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP response morning at week 12 (N=354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP response evening at week 4 (N=354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP response evening at week 8 (N=354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP response evening at week 12 (N=354)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP response morning at week 4 (N=299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP response morning at week 8 (N=299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP response morning at week 12 (N=299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP response evening at week 4 (N=299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP response evening at week 8 (N=299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP response evening at week 12 (N=299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Patients Requiring Up-titration to Telmisartan 80mg Plus Amlodipine 10mg Combination (T80/A10) to Achieve Blood Pressure Control Over Time</title>
        <time_frame>weeks 4 and 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Patients Requiring Up-titration to Telmisartan 80mg Plus Amlodipine 10mg Combination (T80/A10) to Achieve Blood Pressure Control Over Time</title>
          <population>FAS</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks: From drug administration until end of treatment plus one day.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T80/A5</title>
          <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
        </group>
        <group group_id="E2">
          <title>T80/A10</title>
          <description>Telmisartan 80 mg plus Amlodipine 10 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

